Responses
Regular and young investigator award abstracts
Novel single-agent immunotherapies
711 HBM1022, a novel anti-CCR8 antibody depletes tumor-infiltrating regulatory T cells via enhanced ADCC activity, mediates potent anti-tumor activity with Keytruda
Compose a Response to This Article
Other responses
No responses have been published for this article.
